25Pyocin S5 (PyoS5) is a potent protein bacteriocin that eradicates the human pathogen P. 26 aeruginosa in animal infection models, but its import mechanism is poorly understood. Here, 27 using crystallography, biophysical and biochemical analysis and live-cell imaging, we define 28 the entry process of PyoS5 and reveal links to the transport mechanisms of other 29 bacteriocins. In addition to its C-terminal pore-forming domain, elongated PyoS5 comprises 30 two novel tandemly repeated kinked three helix bundle domains that structure-based 31 alignments identify as key import domains in other pyocins. The central domain binds the 32 lipid-bound common polysaccharide antigen, allowing the pyocin to accumulate on the cell 33 surface. The N-terminal domain binds the ferric pyochelin transporter FptA while its 34 associated disordered region binds the inner membrane protein TonB1, which together drive 35 import of the bacteriocin across the outer membrane. Finally, we identify the minimal 36 requirements for sensitizing Escherichia coli towards PyoS5, as well as other pyocins, and 37 suggest that a generic pathway likely underpins the import of all TonB-dependent 38 bacteriocins across the outer membrane of Gram-negative bacteria. 39 40 Word count, 170 41 42 48only the release of bacteriocins does not rely on physical contact between bacterial cells.
49Bacteriocin production generally occurs following a stress signal, such as DNA damage, 50 inducing expression and release of the bacteriocin from auto-lysed cells (Kleanthous, 2010).
51The bacteriocin then diffuses through the medium to kill a neighbouring cell. Bacteriocins 52 range in size, from small peptides to large proteins with both types currently being 53 evaluated/developed as antimicrobials against multidrug resistant bacteria (Rios et al, 2016; 54 Behrens et al, 2017). In many instances, however, developments are hindered by a lack of 55 understanding as to how these molecules work. In the case of protein bacteriocins, 56 extensive sequence diversification and homologous recombination further hamper efforts to 57 find generic mechanisms of uptake. Here, we focus on the uptake mechanism of PyoS5, a 58 protein bacteriocin that specifically targets the opportunistic human pathogen P. aeruginosa 59 and shown recently in animal models to be more effective at clearing lung infections than 60 tobramycin, the antibiotic generally used to treat P. aeruginosa in cystic fibrosis patients 61 (McCaughey et al, 2016b). Through a structure-led approach, we deconstruct the energised 62 uptake pathway of PyoS5 and show that its transport across the outer membrane likely 63 represents the default pathway for all TonB-dependent bacteriocins.
64There is a pressing need for new antibiotics against Gram-negative bacteria but in 65 particular P. aeruginosa which has been designated a priority pathogen (WHO, 2017). The 66 intrinsic low permeability of its outer membrane renders P. aeruginosa insensitive to many 67 classes of antibiotics. Many strains also express mult...